RxDoctor Payments DataLook up a doctor →

Sessine Najjar, MD

Infectious Disease · Clifton, NJNPI 1497862429

Payments from drug & device makers

$12,790in general payments, 2019–2025

Across 878 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • Viiv Healthcare Company$2K
  • Novo Nordisk$1K
  • Johnson & Johnson$1K
  • Merck$959
  • Insmed, Inc.$534
  • plus $4K from 32 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead205$2,705
Viiv Healthcare Company177$2,264
Novo Nordisk83$1,225
Johnson & Johnson(2 entities)70$1,028
Merck60$959
Insmed, Inc.30$534
AbbVie(2 entities)28$417
Lilly USA, LLC27$385
Theratechnologies Inc.24$363
GSK24$352
Sanofi-aventis U.S. LLC16$335
EMD Serono, Inc.17$244
Pfizer14$241
Mannkind Corporation11$210
Amgen12$180
Cumberland Pharmaceuticals, Inc.10$169
Exact Sciences6$128
Paratek Pharmaceuticals, Inc.9$125
Shionogi Inc6$107
Janssen Products, LP2$91
La Jolla Pharmaceutical Company5$90
Boehringer Ingelheim6$89
Phathom Pharmaceuticals, Inc.5$68
Aimmune Therapeutics, Inc.4$67
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$60
AstraZeneca4$58
Kowa Pharmaceuticals America, Inc.3$45
Arbor Pharmaceuticals, Inc.3$38
Napo Pharmaceuticals Inc2$36
Octapharma USA, Inc.1$29
Melinta Therapeutics, LLC2$28
Tetraphase Pharmaceuticals, Inc.2$28
Grifols USA, LLC1$22
Pharming Healthcare, Inc.1$15
Azurity Pharmaceuticals, Inc.1$14
Sanofi Pasteur Inc.1$14
Mylan Institutional Inc.1$13
Teva Pharmaceuticals USA, Inc.1$13

How this compares

$12,790 in reported general payments places this provider in the 85th percentile of 334 infectious disease providers in New Jersey.

See all infectious disease providers in New Jersey →

Medicare billing

Part B allowed, 2024
$206,570
Medicare patients
214
Services billed
98,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Clifton

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →